Cargando…
Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320387/ https://www.ncbi.nlm.nih.gov/pubmed/34391625 http://dx.doi.org/10.1016/j.tracli.2021.07.006 |
| _version_ | 1783730637824327680 |
|---|---|
| author | Franchini, Massimo Baldanti, Fausto Percivalle, Elena Ferrari, Alessandro Biasi, Pietro Liumbruno, Giancarlo Maria Glingani, Claudia |
| author_facet | Franchini, Massimo Baldanti, Fausto Percivalle, Elena Ferrari, Alessandro Biasi, Pietro Liumbruno, Giancarlo Maria Glingani, Claudia |
| author_sort | Franchini, Massimo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8320387 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83203872021-07-29 Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma Franchini, Massimo Baldanti, Fausto Percivalle, Elena Ferrari, Alessandro Biasi, Pietro Liumbruno, Giancarlo Maria Glingani, Claudia Transfus Clin Biol Letter to the Editor Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2022-02 2021-07-29 /pmc/articles/PMC8320387/ /pubmed/34391625 http://dx.doi.org/10.1016/j.tracli.2021.07.006 Text en © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Franchini, Massimo Baldanti, Fausto Percivalle, Elena Ferrari, Alessandro Biasi, Pietro Liumbruno, Giancarlo Maria Glingani, Claudia Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma |
| title | Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma |
| title_full | Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma |
| title_fullStr | Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma |
| title_full_unstemmed | Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma |
| title_short | Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma |
| title_sort | impact of pathogen reduction technology on neutralizing antibody titer in covid-19 convalescent plasma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320387/ https://www.ncbi.nlm.nih.gov/pubmed/34391625 http://dx.doi.org/10.1016/j.tracli.2021.07.006 |
| work_keys_str_mv | AT franchinimassimo impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma AT baldantifausto impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma AT percivalleelena impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma AT ferrarialessandro impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma AT biasipietro impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma AT liumbrunogiancarlomaria impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma AT glinganiclaudia impactofpathogenreductiontechnologyonneutralizingantibodytiterincovid19convalescentplasma |